Practical issues in the treatment of schizophrenia

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14740%2F13%3A00071043" target="_blank" >RIV/00216224:14740/13:00071043 - isvavai.cz</a>

Výsledek na webu

<a href="http://www.scopus.com/record/display.url?eid=2-s2.0-84882412314&origin=resultslist&sort=plf-f&src=s&st1=0391-1772&sid=BE8C6718AF3187DA5FA1E89C09808815.kqQeWtawXauCyC8ghhRGJg%3a620&sot=b&sdt=b&sl=15&s=ISSN%280391-1772%29&relpos=1&relpos=1&citeCnt=0&search" target="_blank" >http://www.scopus.com/record/display.url?eid=2-s2.0-84882412314&origin=resultslist&sort=plf-f&src=s&st1=0391-1772&sid=BE8C6718AF3187DA5FA1E89C09808815.kqQeWtawXauCyC8ghhRGJg%3a620&sot=b&sdt=b&sl=15&s=ISSN%280391-1772%29&relpos=1&relpos=1&citeCnt=0&search</a>

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Practical issues in the treatment of schizophrenia

Popis výsledku v původním jazyce

Treatment should be evidence-based, measurement-based, complex (including pharmacotherapy, psychosocial intervention, and physical health care) and individualized (tailored to the patient). The basis of schizophrenia treatment is still pharmacotherapy. The first generation of antipsychotics (FGAs), known as typical APs, was discovered in the 1950s. Most second generation antipsychotics (SGAs), known as atypical APs, have been developed more recently. SGAs present some advantages in the treatment of certain treatment domains. The binding affinity of APs for specific neuroreceptors is associated with the therapeutic effect, but also with adverse events. The choice of AP for the individual patient should be guided by the side effect profile of the drug, patient experience with certain side effects, previous patient response to certain APs (e.g., individualized treatment), and potential interactions with other prescribed medication.

Název v anglickém jazyce

Practical issues in the treatment of schizophrenia

Popis výsledku anglicky

Treatment should be evidence-based, measurement-based, complex (including pharmacotherapy, psychosocial intervention, and physical health care) and individualized (tailored to the patient). The basis of schizophrenia treatment is still pharmacotherapy. The first generation of antipsychotics (FGAs), known as typical APs, was discovered in the 1950s. Most second generation antipsychotics (SGAs), known as atypical APs, have been developed more recently. SGAs present some advantages in the treatment of certain treatment domains. The binding affinity of APs for specific neuroreceptors is associated with the therapeutic effect, but also with adverse events. The choice of AP for the individual patient should be guided by the side effect profile of the drug, patient experience with certain side effects, previous patient response to certain APs (e.g., individualized treatment), and potential interactions with other prescribed medication.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FL - Psychiatrie, sexuologie

OECD FORD obor

—

Projekt

<a href="/cs/project/ED1.1.00%2F02.0068" target="_blank" >ED1.1.00/02.0068: CEITEC - central european institute of technology</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2013

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Minerva Psichiatrica

ISSN

0391-1772

e-ISSN

—

Svazek periodika

54

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

IT - Italská republika

Počet stran výsledku

13

Strana od-do

101-113

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—